Core Insights - Genenta Science is conducting ongoing clinical trials for its immuno-oncology product, Temferon, focusing on glioblastoma multiforme and genitourinary tumors [1][3][6] Group 1: Glioblastoma Multiforme Study - A total of 38 patients have been enrolled in the glioblastoma multiforme study, with 25 patients receiving Temferon [1] - The two-year survival rate for unmethylated MGMT (uMGMT) patients in the GBM trial is 29%, with a median overall survival of 17 months, compared to historical cohorts showing a 14% survival rate and a median overall survival of 13 to 15 months [2] - Two patients have been enrolled in a long-term follow-up study, with one showing no disease progression and the other stabilizing after initial progression, indicating potential efficacy of Temferon [1] Group 2: Genitourinary Tumor Study - The TEM-GU Phase 1 study has begun recruitment, aiming to enroll 12 patients with genitourinary tumors, administering Temferon at a fixed dose of 4 million genetically modified cells per kilogram [3] - The study will evaluate the safety and tolerability of Temferon in combination with immune checkpoint inhibitors or tyrosine kinase inhibitors [3] Group 3: Mechanism of Action - Temferon works by reprogramming the tumor microenvironment to enhance adaptive immune responses [4] - A scientific manuscript has been accepted for publication, demonstrating Temferon's potential to enhance CAR-T activity in preclinical models [4][5] Group 4: Company Overview - Genenta Science is a clinical-stage immuno-oncology company developing hematopoietic stem cell therapy for solid tumors, with Temferon as its first product candidate [6] - The company has completed a Phase 1 trial for newly diagnosed GBM patients with an unmethylated MGMT gene promoter, suggesting potential for reprogramming the tumor microenvironment [6]

This collaboration represents a pivotal step in the advancement of immuno-oncology therapies, highlighting the powerful synergy between Genenta's innovative platform and Anemocyte's proven expertise in the production of high-quality starting materials. Forward-Looking Statements MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturi ...

Core Insights - Genenta Science, a leader in immuno-oncology and cell-based therapeutics, is advancing its pipeline with a strategic financing of €20 million ($22.7 million) through a Mandatory Convertible Bond to ENEA Tech and Biomedical [2] - The company is focused on the development of Temferon™ for metastatic Renal Cell Cancer (mRCC) and has raised an additional €3.0 million ($3.2 million) via an at-the-market facility [2] - CEO Pierluigi Paracchi will present at the "Montalcini Global Biotech Tour" in Doha, Qatar, highlighting the Italian biotech ecosystem and the company's initiatives [1][3] Company Developments - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients, indicating potential for reprogramming the tumor microenvironment [6] - The company has initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will explore combinations with immune checkpoint inhibitors [6] - Temferon™ is designed to express immune-therapeutic payloads within the tumor microenvironment, aiming for a durable and targeted response [6] Strategic Partnerships - The event in Doha will feature key stakeholders, including representatives from the Qatar Investment Authority, which manages over $475 billion in assets, indicating potential for cross-border partnerships [4] - CDP Venture Capital, a long-standing investor in Genenta, participated in the company's IPO on Nasdaq in 2021, showcasing ongoing support from institutional investors [3]